[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCVv5mCZKvrZUc4z7a5f4uyAeTgUrrqrjTDf22nXcUmM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Institut du Cancer de Montpellier - Val d'Aurelle",[4],141,false,63,8,38529,27,87,[14,17,19,22,25,28,30,33],{"name":15,"count":16},"Breast Cancer",40,{"name":18,"count":9},"Cancer",{"name":20,"count":21},"Colorectal Cancer",7,{"name":23,"count":24},"Rectal Cancer",6,{"name":26,"count":27},"Prostate Cancer",5,{"name":29,"count":27},"Head and Neck Cancer",{"name":31,"count":32},"Glioma",4,{"name":34,"count":32},"Metastatic Colorectal Cancer",[36,41,46,51,56,61,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03252717","Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)","2017-08-31","Blood sample",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04224779","Liquid Biopsies and IMAging for Improved Cancer Care","2022-05-31","Biological collection",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03255434","LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy","2022-07-28","Oxaliplatin",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03829462","Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","2024-09-04","Regorafenib",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04356209","Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic \" Patient Reported Outcome \") on Breast-related Quality of Life","2026-01-31","Pravastatin",{"nctId":62,"briefTitle":63,"date":64,"intervention":45},"NCT05257135","A Clinico-biological Database in Cachexia in Patients With Colon Cancer","2026-05",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04025541","Analysis of Circulating Tumor Markers in Blood","2026-05-29","Blood sampling",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT04749108","Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","2026-08","Induction chemotherapy - modified FOLFIRINOX regimen",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06084195","Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging","2026-10","Blood sample and tissue sample",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04282356","Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer","2026-12","Intraperitoneal chemotherapy during surgery",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,132,161,184,272,295,322,340,361,388,414,439,457,510,548,574,604,622,640,658,676,694,712,730,748,772,798,818,859,883,907,925,943,961,979,997,1022,1079,1105,1133,1155,1173,1201,1219,1237,1262,1280,1298,1316,1334,1352,1376,1401,1419,1444,1465,1489,1507,1525,1551,1569,1594,1612,1630,1653,1679,1697,1715,1733,1757,1781,1806,1829,1854],{"intervention":55,"totalTrials":94,"cells":95},2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":115,"PHASE4":128,"NA":130},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[103],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT02386397","Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer","COMPLETED",[87,88],"2019-12","2014-09",66,[112],"Digestive Cancer",[55,114],"GEMOX",{"trials":116,"activeCount":127,"soonestReadout":54},[117],{"nctId":52,"briefTitle":53,"status":118,"phases":119,"primaryCompletion":54,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"ACTIVE_NOT_RECRUITING",[89],"2026-09","2019-03-28",377,[124],"Metastatic Colorectal Cancer (mCRC)",[55,126],"Irinotecan",1,{"trials":129,"activeCount":98},[],{"trials":131,"activeCount":98},[],{"intervention":126,"totalTrials":94,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":149,"PHASE3":151,"PHASE4":157,"NA":159},{"trials":135,"activeCount":98},[],{"trials":137,"activeCount":98},[138],{"nctId":139,"briefTitle":140,"status":106,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"NCT02387138","A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan",[87],"2018-06","2018-09","2014-04",24,[112],[148,126,50],"S-1",{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":127,"soonestReadout":54},[153],{"nctId":52,"briefTitle":53,"status":118,"phases":154,"primaryCompletion":54,"completion":120,"start":121,"enrollment":122,"conditions":155,"interventions":156},[89],[124],[55,126],{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"intervention":74,"totalTrials":127,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":180,"NA":182},{"trials":164,"activeCount":98},[],{"trials":166,"activeCount":98},[],{"trials":168,"activeCount":98},[],{"trials":170,"activeCount":127,"soonestReadout":73},[171],{"nctId":71,"briefTitle":72,"status":172,"phases":173,"primaryCompletion":73,"completion":73,"start":174,"enrollment":175,"conditions":176,"interventions":179},"RECRUITING",[88,89],"2021-11-26",1075,[177,178],"Locally Advanced Malignant Neoplasm","Rectal Carcinoma",[74],{"trials":181,"activeCount":98},[],{"trials":183,"activeCount":98},[],{"intervention":185,"totalTrials":21,"cells":186},"oxaliplatin",{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":219,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":188,"activeCount":98},[],{"trials":190,"activeCount":98},[191,195,207],{"nctId":139,"briefTitle":140,"status":106,"phases":192,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":193,"interventions":194},[87],[112],[148,126,50],{"nctId":196,"briefTitle":197,"status":106,"phases":198,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":203,"interventions":204},"NCT03253133","Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC",[87],"2020-10-28","2023-04-24","2016-05-10",19,[20],[50,205,206],"LV5FU or Folfiri","Oxycodone",{"nctId":208,"briefTitle":209,"status":210,"phases":211,"primaryCompletion":212,"start":213,"enrollment":214,"conditions":215,"interventions":217},"NCT00544063","Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer","UNKNOWN",[87],"2011-12","2006-10",33,[216],"Unspecified Adult Solid Tumor, Protocol Specific",[218,185],"irinotecan hydrochloride",{"trials":220,"activeCount":127,"soonestReadout":49},[221,234,247,257],{"nctId":222,"briefTitle":223,"status":106,"phases":224,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":230},"NCT00556413","Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",[88],"2011-05","2011-11-17","2005-09",42,[20],[231,232,218,233,185],"cetuximab","fluorouracil","leucovorin calcium",{"nctId":235,"briefTitle":236,"status":106,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT00941967","Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer",[88],"2010-12","2012-12","2008-12",78,[243],"Liver Cancer",[245,185,246],"gemcitabine hydrochloride","sorafenib tosylate",{"nctId":248,"briefTitle":249,"status":106,"phases":250,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":256},"NCT00627432","Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer",[88],"2009-03","2004-07",44,[255],"Bladder Cancer",[245,185],{"nctId":47,"briefTitle":48,"status":118,"phases":258,"primaryCompletion":49,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},[88],"2025-07-31","2017-11-01",160,[263],"Stage III Colon Cancer",[50,265],"Oxaliplatin LBM",{"trials":267,"activeCount":98},[],{"trials":269,"activeCount":98},[],{"trials":271,"activeCount":98},[],{"intervention":84,"totalTrials":127,"cells":273},{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":127,"soonestReadout":83},[280],{"nctId":81,"briefTitle":82,"status":172,"phases":281,"primaryCompletion":83,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":288},[88],"2030-12","2020-09-15",55,[286,287],"Ovarian Cancer","Intraperitoneal Chemotherapy",[84],{"trials":290,"activeCount":98},[],{"trials":292,"activeCount":98},[],{"trials":294,"activeCount":98},[],{"intervention":296,"totalTrials":127,"cells":297},"GEMBRAX\u002FFOLFIRINOX Arm A",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":127,"soonestReadout":308},[304],{"nctId":305,"briefTitle":306,"status":172,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT05065801","Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients",[88],"2026-12-30","2028-06-30","2022-01-11",162,[313],"Metastatic Pancreatic Cancer",[296,315],"FOLFIRINOX Arm B",{"trials":317,"activeCount":98},[],{"trials":319,"activeCount":98},[],{"trials":321,"activeCount":98},[],{"intervention":315,"totalTrials":127,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":325,"activeCount":98},[],{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":127,"soonestReadout":308},[330],{"nctId":305,"briefTitle":306,"status":172,"phases":331,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":332,"interventions":333},[88],[313],[296,315],{"trials":335,"activeCount":98},[],{"trials":337,"activeCount":98},[],{"trials":339,"activeCount":98},[],{"intervention":60,"totalTrials":127,"cells":341},{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":343,"activeCount":98},[],{"trials":345,"activeCount":98},[],{"trials":347,"activeCount":127,"soonestReadout":59},[348],{"nctId":57,"briefTitle":58,"status":172,"phases":349,"primaryCompletion":59,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":354},[88],"2031-01-31","2020-01-31",105,[15],[60],{"trials":356,"activeCount":98},[],{"trials":358,"activeCount":98},[],{"trials":360,"activeCount":98},[],{"intervention":362,"totalTrials":127,"cells":363},"Lutathera",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":98},[],{"trials":369,"activeCount":127,"soonestReadout":374},[370],{"nctId":371,"briefTitle":372,"status":172,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":381},"NCT04954820","Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET",[88],"2031-10","2021-10-18",146,[378,379,380],"Neuroendocrine Tumors","Intestinal Well Differentiated Endocrine Tumor","Progressive Disease",[362],{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"trials":387,"activeCount":98},[],{"intervention":389,"totalTrials":127,"cells":390},"standard radiotherapy with chemotherapy",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":392,"activeCount":98},[],{"trials":394,"activeCount":98},[],{"trials":396,"activeCount":127,"soonestReadout":402},[397],{"nctId":398,"briefTitle":399,"status":400,"phases":401,"primaryCompletion":402,"completion":403,"start":404,"enrollment":261,"conditions":405,"interventions":407},"NCT07097064","Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers","NOT_YET_RECRUITING",[88],"2028-09","2033-09","2025-09",[406],"Locally Advanced Pancreatic Adenocarcinoma",[389],{"trials":409,"activeCount":98},[],{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":98},[],{"intervention":415,"totalTrials":127,"cells":416},"Gabrinox",{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":418,"activeCount":98},[],{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":127,"soonestReadout":427},[423],{"nctId":424,"briefTitle":425,"status":172,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":432},"NCT04570943","Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer",[88],"2028-01","2030-06","2021-06-16",103,[406],[415],{"trials":434,"activeCount":98},[],{"trials":436,"activeCount":98},[],{"trials":438,"activeCount":98},[],{"intervention":265,"totalTrials":127,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":442,"activeCount":98},[],{"trials":444,"activeCount":98},[],{"trials":446,"activeCount":127,"soonestReadout":49},[447],{"nctId":47,"briefTitle":48,"status":118,"phases":448,"primaryCompletion":49,"completion":259,"start":260,"enrollment":261,"conditions":449,"interventions":450},[88],[263],[50,265],{"trials":452,"activeCount":98},[],{"trials":454,"activeCount":98},[],{"trials":456,"activeCount":98},[],{"intervention":458,"totalTrials":32,"cells":459},"biological collection",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":470},{"trials":461,"activeCount":98},[],{"trials":463,"activeCount":98},[],{"trials":465,"activeCount":98},[],{"trials":467,"activeCount":98},[],{"trials":469,"activeCount":98},[],{"trials":471,"activeCount":32,"soonestReadout":44},[472,483,490,498],{"nctId":473,"briefTitle":474,"status":172,"phases":475,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":482},"NCT04221464","Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)",[91],"2028-02","2038-02","2019-11-25",600,[18,481],"Peritoneal Carcinosis",[458],{"nctId":42,"briefTitle":43,"status":118,"phases":484,"primaryCompletion":44,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":489},[91],"2027-05","2021-02-18",16,[23],[45],{"nctId":62,"briefTitle":63,"status":172,"phases":491,"primaryCompletion":64,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},[91],"2029-05","2021-12-23",150,[496],"Colon Cancer",[45],{"nctId":499,"briefTitle":500,"status":172,"phases":501,"primaryCompletion":502,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":509},"NCT03449264","Development of Clinical and Biological Database",[91],"2027-11","2037-11","2017-07-27",4000,[112,507,15,508],"Gynecologic Cancer","Sarcoma",[458],{"intervention":40,"totalTrials":511,"cells":512},3,{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":514,"activeCount":98},[],{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":98},[],{"trials":524,"activeCount":127,"soonestReadout":39},[525,534,540],{"nctId":526,"briefTitle":527,"status":106,"phases":528,"primaryCompletion":529,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":533},"NCT03255486","Identification and Evaluation of Biomarkers of Resistance to Neoadjuvant Chemotherapy (IDEA SEIN)",[91],"2016-12","2013-07",164,[15],[40],{"nctId":37,"briefTitle":38,"status":118,"phases":535,"primaryCompletion":39,"start":536,"enrollment":537,"conditions":538,"interventions":539},[91],"2014-08",500,[15],[40],{"nctId":541,"briefTitle":542,"status":106,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":376,"conditions":546,"interventions":547},"NCT03249389","Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS)",[91],"2016-09","2015-10",[15],[40],{"intervention":549,"totalTrials":127,"cells":550},"Blood and tissue sampling",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":561},{"trials":552,"activeCount":98},[],{"trials":554,"activeCount":98},[],{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[],{"trials":562,"activeCount":127,"soonestReadout":567},[563],{"nctId":564,"briefTitle":565,"status":400,"phases":566,"primaryCompletion":567,"completion":568,"start":404,"enrollment":569,"conditions":570,"interventions":573},"NCT07085429","Development of Clinical and Biological Database on Bronchial Cancer",[91],"2030-09","2040-09",750,[571,572],"Lung Cancer","Bronchial Cancer",[549],{"intervention":69,"totalTrials":127,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":577,"activeCount":98},[],{"trials":579,"activeCount":98},[],{"trials":581,"activeCount":98},[],{"trials":583,"activeCount":98},[],{"trials":585,"activeCount":98},[],{"trials":587,"activeCount":127,"soonestReadout":68},[588],{"nctId":66,"briefTitle":67,"status":172,"phases":589,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":595},[91],"2029-05-29","2018-05-29",992,[18,15,508,594,31,496],"Lung Cancers",[69,596,597,598,599,600,601,602,603],"Blood sampling C3","Blood sampling C4\u002F7\u002F10\u002F13","Blood sampling C5","Blood sampling C6","Blood sampling C8","Blood sampling C9","Blood sampling C11 + FFPE","Blood sampling C12",{"intervention":596,"totalTrials":127,"cells":605},{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":614,"NA":616},{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":98},[],{"trials":613,"activeCount":98},[],{"trials":615,"activeCount":98},[],{"trials":617,"activeCount":127,"soonestReadout":68},[618],{"nctId":66,"briefTitle":67,"status":172,"phases":619,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":620,"interventions":621},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":597,"totalTrials":127,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":625,"activeCount":98},[],{"trials":627,"activeCount":98},[],{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":98},[],{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":127,"soonestReadout":68},[636],{"nctId":66,"briefTitle":67,"status":172,"phases":637,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":638,"interventions":639},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":598,"totalTrials":127,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":643,"activeCount":98},[],{"trials":645,"activeCount":98},[],{"trials":647,"activeCount":98},[],{"trials":649,"activeCount":98},[],{"trials":651,"activeCount":98},[],{"trials":653,"activeCount":127,"soonestReadout":68},[654],{"nctId":66,"briefTitle":67,"status":172,"phases":655,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":656,"interventions":657},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":599,"totalTrials":127,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":670},{"trials":661,"activeCount":98},[],{"trials":663,"activeCount":98},[],{"trials":665,"activeCount":98},[],{"trials":667,"activeCount":98},[],{"trials":669,"activeCount":98},[],{"trials":671,"activeCount":127,"soonestReadout":68},[672],{"nctId":66,"briefTitle":67,"status":172,"phases":673,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":674,"interventions":675},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":600,"totalTrials":127,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":688},{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[],{"trials":687,"activeCount":98},[],{"trials":689,"activeCount":127,"soonestReadout":68},[690],{"nctId":66,"briefTitle":67,"status":172,"phases":691,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":692,"interventions":693},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":601,"totalTrials":127,"cells":695},{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":706},{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[],{"trials":701,"activeCount":98},[],{"trials":703,"activeCount":98},[],{"trials":705,"activeCount":98},[],{"trials":707,"activeCount":127,"soonestReadout":68},[708],{"nctId":66,"briefTitle":67,"status":172,"phases":709,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":710,"interventions":711},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":602,"totalTrials":127,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":724},{"trials":715,"activeCount":98},[],{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[],{"trials":723,"activeCount":98},[],{"trials":725,"activeCount":127,"soonestReadout":68},[726],{"nctId":66,"briefTitle":67,"status":172,"phases":727,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":728,"interventions":729},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":603,"totalTrials":127,"cells":731},{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":738,"PHASE4":740,"NA":742},{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"trials":741,"activeCount":98},[],{"trials":743,"activeCount":127,"soonestReadout":68},[744],{"nctId":66,"briefTitle":67,"status":172,"phases":745,"primaryCompletion":68,"completion":590,"start":591,"enrollment":592,"conditions":746,"interventions":747},[91],[18,15,508,594,31,496],[69,596,597,598,599,600,601,602,603],{"intervention":749,"totalTrials":127,"cells":750},"Biological\u002FVaccine: Blood sample and tissue sample",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":127,"soonestReadout":767},[763],{"nctId":764,"briefTitle":765,"status":172,"phases":766,"primaryCompletion":767,"completion":767,"start":768,"enrollment":494,"conditions":769,"interventions":771},"NCT06144762","Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer",[91],"2029-10","2023-12-19",[770],"Pancreas Cancer",[749],{"intervention":773,"totalTrials":127,"cells":774},"Blood sampling C1",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":785},{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":127,"soonestReadout":791},[787],{"nctId":788,"briefTitle":789,"status":400,"phases":790,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":797},"NCT07060950","Analysis of Circulating Tumor Markers in Blood - ALCINA 5",[91],"2030-07","2035-07","2025-10",620,[18,796],"Lung Cancer, Non-Small Cell",[773],{"intervention":79,"totalTrials":127,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":801,"activeCount":98},[],{"trials":803,"activeCount":98},[],{"trials":805,"activeCount":98},[],{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":127,"soonestReadout":78},[812],{"nctId":76,"briefTitle":77,"status":172,"phases":813,"primaryCompletion":78,"completion":767,"start":768,"enrollment":814,"conditions":815,"interventions":817},[91],120,[816],"High Grade Serous Ovarian Cancer",[79],{"intervention":819,"totalTrials":94,"cells":820},"FOLFIRINOX",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":838,"PHASE4":855,"NA":857},{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":98},[827],{"nctId":828,"briefTitle":829,"status":106,"phases":830,"primaryCompletion":831,"completion":832,"start":833,"enrollment":241,"conditions":834,"interventions":836},"NCT01964287","First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.",[87,88],"2016-12-22","2020-12-30","2013-09-24",[835],"Metastatic Pancreatic Adenocarcinoma",[837,819],"GEMBRAX",{"trials":839,"activeCount":98},[840],{"nctId":841,"briefTitle":842,"status":106,"phases":843,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":850},"NCT00208260","Intensified Chemotherapy in CRC After Resection of Liver Metastases",[88,89],"2007-08","2004-04",124,[20,848,849],"Liver Metastases","Chemotherapy",[851,852,853,854,819],"FOLFIRI","FOLFOX-4","FOLFIRI-HD","FOLFOX-7",{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"intervention":860,"totalTrials":127,"cells":861},"calcium and cholecalciferol",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":879,"NA":881},{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[],{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":98},[870],{"nctId":871,"briefTitle":872,"status":106,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":878},"NCT01480869","Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients",[89],"2014-12","2011-07",215,[15],[860,860],{"trials":880,"activeCount":98},[],{"trials":882,"activeCount":98},[],{"intervention":884,"totalTrials":127,"cells":885},"letrozole",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":903,"NA":905},{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[],{"trials":891,"activeCount":98},[],{"trials":893,"activeCount":98},[894],{"nctId":895,"briefTitle":896,"status":106,"phases":897,"primaryCompletion":898,"completion":898,"start":240,"enrollment":899,"conditions":900,"interventions":901},"NCT00949598","Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer",[89],"2010-10",177,[15],[884,902],"tamoxifen citrate",{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"intervention":902,"totalTrials":127,"cells":908},{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":921,"NA":923},{"trials":910,"activeCount":98},[],{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[917],{"nctId":895,"briefTitle":896,"status":106,"phases":918,"primaryCompletion":898,"completion":898,"start":240,"enrollment":899,"conditions":919,"interventions":920},[89],[15],[884,902],{"trials":922,"activeCount":98},[],{"trials":924,"activeCount":98},[],{"intervention":851,"totalTrials":127,"cells":926},{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":939,"NA":941},{"trials":928,"activeCount":98},[],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[935],{"nctId":841,"briefTitle":842,"status":106,"phases":936,"completion":844,"start":845,"enrollment":846,"conditions":937,"interventions":938},[88,89],[20,848,849],[851,852,853,854,819],{"trials":940,"activeCount":98},[],{"trials":942,"activeCount":98},[],{"intervention":852,"totalTrials":127,"cells":944},{"EARLY_PHASE1":945,"PHASE1":947,"PHASE2":949,"PHASE3":951,"PHASE4":957,"NA":959},{"trials":946,"activeCount":98},[],{"trials":948,"activeCount":98},[],{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[953],{"nctId":841,"briefTitle":842,"status":106,"phases":954,"completion":844,"start":845,"enrollment":846,"conditions":955,"interventions":956},[88,89],[20,848,849],[851,852,853,854,819],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"intervention":853,"totalTrials":127,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":975,"NA":977},{"trials":964,"activeCount":98},[],{"trials":966,"activeCount":98},[],{"trials":968,"activeCount":98},[],{"trials":970,"activeCount":98},[971],{"nctId":841,"briefTitle":842,"status":106,"phases":972,"completion":844,"start":845,"enrollment":846,"conditions":973,"interventions":974},[88,89],[20,848,849],[851,852,853,854,819],{"trials":976,"activeCount":98},[],{"trials":978,"activeCount":98},[],{"intervention":854,"totalTrials":127,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":993,"NA":995},{"trials":982,"activeCount":98},[],{"trials":984,"activeCount":98},[],{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":98},[989],{"nctId":841,"briefTitle":842,"status":106,"phases":990,"completion":844,"start":845,"enrollment":846,"conditions":991,"interventions":992},[88,89],[20,848,849],[851,852,853,854,819],{"trials":994,"activeCount":98},[],{"trials":996,"activeCount":98},[],{"intervention":998,"totalTrials":127,"cells":999},"EXPERIMENTAL ARM",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1018,"NA":1020},{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":98},[],{"trials":1007,"activeCount":98},[1008],{"nctId":1009,"briefTitle":1010,"status":1011,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1017},"NCT04385433","A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer","TERMINATED",[89],"2023-04-27","2020-12-04",15,[15],[998],{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"intervention":1023,"totalTrials":32,"cells":1024},"Cisplatin",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1073,"PHASE4":1075,"NA":1077},{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[],{"trials":1030,"activeCount":98},[1031,1043,1052,1065],{"nctId":1032,"briefTitle":1033,"status":1011,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1041},"NCT03255252","Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy",[88],"2022-06-16","2023-11-23","2017-07-15",29,[1040],"Cervical Cancer",[1023,1042],"radiotherapy",{"nctId":1044,"briefTitle":1045,"status":106,"phases":1046,"primaryCompletion":225,"completion":225,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1050},"NCT00559156","Arginine\u002FOmega-3 Fatty Acids\u002FNucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy",[88],"2005-06",46,[29],[1051],"cisplatin",{"nctId":1053,"briefTitle":1054,"status":1055,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":110,"conditions":1060,"interventions":1063},"NCT03875144","Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)","SUSPENDED",[88],"2024-12-16","2027-06","2020-09-10",[1061,1062],"Peritoneal Mesothelioma","Peritoneal Carcinomatosis",[1023,1064],"Pemetrexed",{"nctId":1066,"briefTitle":1067,"status":106,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1047,"enrollment":1070,"conditions":1071,"interventions":1072},"NCT00556621","Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer",[87,88],"2009-08",14,[255],[1051,245],{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":98},[],{"trials":1078,"activeCount":98},[],{"intervention":245,"totalTrials":511,"cells":1080},{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1082,"activeCount":98},[],{"trials":1084,"activeCount":98},[],{"trials":1086,"activeCount":98},[1087,1091,1095],{"nctId":235,"briefTitle":236,"status":106,"phases":1088,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":1089,"interventions":1090},[88],[243],[245,185,246],{"nctId":248,"briefTitle":249,"status":106,"phases":1092,"primaryCompletion":251,"completion":251,"start":252,"enrollment":253,"conditions":1093,"interventions":1094},[88],[255],[245,185],{"nctId":1066,"briefTitle":1067,"status":106,"phases":1096,"primaryCompletion":1069,"completion":1069,"start":1047,"enrollment":1070,"conditions":1097,"interventions":1098},[87,88],[255],[1051,245],{"trials":1100,"activeCount":98},[],{"trials":1102,"activeCount":98},[],{"trials":1104,"activeCount":98},[],{"intervention":231,"totalTrials":94,"cells":1106},{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1108,"activeCount":98},[],{"trials":1110,"activeCount":98},[],{"trials":1112,"activeCount":98},[1113,1117],{"nctId":222,"briefTitle":223,"status":106,"phases":1114,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":1115,"interventions":1116},[88],[20],[231,232,218,233,185],{"nctId":1118,"briefTitle":1119,"status":106,"phases":1120,"primaryCompletion":1121,"completion":1122,"start":240,"enrollment":214,"conditions":1123,"interventions":1125},"NCT00923299","Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine",[87,88],"2010-04","2011-03",[1124],"Pancreatic Cancer",[231,1126],"trastuzumab",{"trials":1128,"activeCount":98},[],{"trials":1130,"activeCount":98},[],{"trials":1132,"activeCount":98},[],{"intervention":218,"totalTrials":94,"cells":1134},{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1143,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1136,"activeCount":98},[],{"trials":1138,"activeCount":98},[1139],{"nctId":208,"briefTitle":209,"status":210,"phases":1140,"primaryCompletion":212,"start":213,"enrollment":214,"conditions":1141,"interventions":1142},[87],[216],[218,185],{"trials":1144,"activeCount":98},[1145],{"nctId":222,"briefTitle":223,"status":106,"phases":1146,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":1147,"interventions":1148},[88],[20],[231,232,218,233,185],{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[],{"intervention":1042,"totalTrials":127,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":98},[],{"trials":1162,"activeCount":98},[1163],{"nctId":1032,"briefTitle":1033,"status":1011,"phases":1164,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":1038,"conditions":1165,"interventions":1166},[88],[1040],[1023,1042],{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"intervention":1174,"totalTrials":127,"cells":1175},"Sorafenib and irinotecan combination",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1177,"activeCount":98},[],{"trials":1179,"activeCount":98},[],{"trials":1181,"activeCount":98},[1182],{"nctId":1183,"briefTitle":1184,"status":106,"phases":1185,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1190,"interventions":1192},"NCT01715441","Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors",[88],"2015-03","2015-09","2012-09",173,[1191],"Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors",[1174,1193,1194],"Sorafenib monotherapy","Irinotecan monotherapy",{"trials":1196,"activeCount":98},[],{"trials":1198,"activeCount":98},[],{"trials":1200,"activeCount":98},[],{"intervention":1193,"totalTrials":127,"cells":1202},{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[1209],{"nctId":1183,"briefTitle":1184,"status":106,"phases":1210,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1211,"interventions":1212},[88],[1191],[1174,1193,1194],{"trials":1214,"activeCount":98},[],{"trials":1216,"activeCount":98},[],{"trials":1218,"activeCount":98},[],{"intervention":1194,"totalTrials":127,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":98},[1227],{"nctId":1183,"briefTitle":1184,"status":106,"phases":1228,"primaryCompletion":1186,"completion":1187,"start":1188,"enrollment":1189,"conditions":1229,"interventions":1230},[88],[1191],[1174,1193,1194],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"intervention":1238,"totalTrials":127,"cells":1239},"Letrozole - Concomitant",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[1246],{"nctId":1247,"briefTitle":1248,"status":106,"phases":1249,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":494,"conditions":1253,"interventions":1254},"NCT00208273","Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer",[88],"2007-01","2007-02","2005-01",[15],[1238,1255],"Letrozole - Sequential",{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[],{"intervention":1255,"totalTrials":127,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1265,"activeCount":98},[],{"trials":1267,"activeCount":98},[],{"trials":1269,"activeCount":98},[1270],{"nctId":1247,"briefTitle":1248,"status":106,"phases":1271,"primaryCompletion":1250,"completion":1251,"start":1252,"enrollment":494,"conditions":1272,"interventions":1273},[88],[15],[1238,1255],{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[],{"intervention":837,"totalTrials":127,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1292,"PHASE4":1294,"NA":1296},{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":98},[1288],{"nctId":828,"briefTitle":829,"status":106,"phases":1289,"primaryCompletion":831,"completion":832,"start":833,"enrollment":241,"conditions":1290,"interventions":1291},[87,88],[835],[837,819],{"trials":1293,"activeCount":98},[],{"trials":1295,"activeCount":98},[],{"trials":1297,"activeCount":98},[],{"intervention":114,"totalTrials":127,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1310,"PHASE4":1312,"NA":1314},{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[1306],{"nctId":104,"briefTitle":105,"status":106,"phases":1307,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":1308,"interventions":1309},[87,88],[112],[55,114],{"trials":1311,"activeCount":98},[],{"trials":1313,"activeCount":98},[],{"trials":1315,"activeCount":98},[],{"intervention":232,"totalTrials":127,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"trials":1323,"activeCount":98},[1324],{"nctId":222,"briefTitle":223,"status":106,"phases":1325,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":1326,"interventions":1327},[88],[20],[231,232,218,233,185],{"trials":1329,"activeCount":98},[],{"trials":1331,"activeCount":98},[],{"trials":1333,"activeCount":98},[],{"intervention":233,"totalTrials":127,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1346,"PHASE4":1348,"NA":1350},{"trials":1337,"activeCount":98},[],{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[1342],{"nctId":222,"briefTitle":223,"status":106,"phases":1343,"primaryCompletion":225,"completion":226,"start":227,"enrollment":228,"conditions":1344,"interventions":1345},[88],[20],[231,232,218,233,185],{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"intervention":1353,"totalTrials":127,"cells":1354},"Gemcitabine - Trastuzumab - Erlotinib",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[1361],{"nctId":1362,"briefTitle":1363,"status":106,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":8,"conditions":1368,"interventions":1369},"NCT01204372","Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma",[88],"2012-02","2016-08","2010-06",[835],[1353],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"intervention":1377,"totalTrials":127,"cells":1378},"fotemustine",{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[1385],{"nctId":1386,"briefTitle":1387,"status":1011,"phases":1388,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":1391,"conditions":1392,"interventions":1394},"NCT00560118","Fotemustine in Treating Patients With Metastatic Melanoma",[88],"2008-08-31","2003-08-08",12,[1393],"Melanoma (Skin)",[1377],{"trials":1396,"activeCount":98},[],{"trials":1398,"activeCount":98},[],{"trials":1400,"activeCount":98},[],{"intervention":246,"totalTrials":127,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[1409],{"nctId":235,"briefTitle":236,"status":106,"phases":1410,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":1411,"interventions":1412},[88],[243],[245,185,246],{"trials":1414,"activeCount":98},[],{"trials":1416,"activeCount":98},[],{"trials":1418,"activeCount":98},[],{"intervention":1420,"totalTrials":127,"cells":1421},"Folfirinox + regorafenib",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1438,"PHASE4":1440,"NA":1442},{"trials":1423,"activeCount":98},[],{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[1428],{"nctId":1429,"briefTitle":1430,"status":106,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":1435,"conditions":1436,"interventions":1437},"NCT03828799","Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer",[87,88],"2021-12-02","2024-11-30","2019-05-14",13,[34],[1420],{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":98},[],{"trials":1443,"activeCount":98},[],{"intervention":1445,"totalTrials":127,"cells":1446},"Induction trichemotherapy - FOLFIRINOX regimen",{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1459,"PHASE4":1461,"NA":1463},{"trials":1448,"activeCount":98},[],{"trials":1450,"activeCount":98},[],{"trials":1452,"activeCount":98},[1453],{"nctId":1454,"briefTitle":1455,"status":106,"phases":1456,"primaryCompletion":109,"completion":109,"start":225,"enrollment":494,"conditions":1457,"interventions":1458},"NCT01333709","Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma",[88],[177,178],[1445],{"trials":1460,"activeCount":98},[],{"trials":1462,"activeCount":98},[],{"trials":1464,"activeCount":98},[],{"intervention":1466,"totalTrials":127,"cells":1467},"Nexavar",{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1469,"activeCount":98},[],{"trials":1471,"activeCount":98},[],{"trials":1473,"activeCount":98},[1474],{"nctId":1475,"briefTitle":1476,"status":106,"phases":1477,"primaryCompletion":1478,"completion":1365,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1482},"NCT00989469","Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation",[87,88],"2011-02","2009-02",64,[34],[1466],{"trials":1484,"activeCount":98},[],{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[],{"intervention":1064,"totalTrials":127,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1495,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1492,"activeCount":98},[],{"trials":1494,"activeCount":98},[],{"trials":1496,"activeCount":98},[1497],{"nctId":1053,"briefTitle":1054,"status":1055,"phases":1498,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":110,"conditions":1499,"interventions":1500},[88],[1061,1062],[1023,1064],{"trials":1502,"activeCount":98},[],{"trials":1504,"activeCount":98},[],{"trials":1506,"activeCount":98},[],{"intervention":1126,"totalTrials":127,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1510,"activeCount":98},[],{"trials":1512,"activeCount":98},[],{"trials":1514,"activeCount":98},[1515],{"nctId":1118,"briefTitle":1119,"status":106,"phases":1516,"primaryCompletion":1121,"completion":1122,"start":240,"enrollment":214,"conditions":1517,"interventions":1518},[87,88],[1124],[231,1126],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[],{"intervention":1526,"totalTrials":127,"cells":1527},"bevacizumab, oxaliplatin and 5FU combination",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1545,"PHASE4":1547,"NA":1549},{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[],{"trials":1533,"activeCount":98},[1534],{"nctId":1535,"briefTitle":1536,"status":1011,"phases":1537,"primaryCompletion":1538,"completion":1539,"start":1540,"enrollment":1541,"conditions":1542,"interventions":1543},"NCT01532804","2nd-line Treatment of Metastatic Colorectal Cancer",[88],"2016-05-12","2019-01","2011-07-28",83,[34],[1526,1544],"Bevacizumab, oxaliplatin and raltitrexed combination",{"trials":1546,"activeCount":98},[],{"trials":1548,"activeCount":98},[],{"trials":1550,"activeCount":98},[],{"intervention":1544,"totalTrials":127,"cells":1552},{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1563,"PHASE4":1565,"NA":1567},{"trials":1554,"activeCount":98},[],{"trials":1556,"activeCount":98},[],{"trials":1558,"activeCount":98},[1559],{"nctId":1535,"briefTitle":1536,"status":1011,"phases":1560,"primaryCompletion":1538,"completion":1539,"start":1540,"enrollment":1541,"conditions":1561,"interventions":1562},[88],[34],[1526,1544],{"trials":1564,"activeCount":98},[],{"trials":1566,"activeCount":98},[],{"trials":1568,"activeCount":98},[],{"intervention":1570,"totalTrials":127,"cells":1571},"bicalutamide",{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1586,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1573,"activeCount":98},[],{"trials":1575,"activeCount":98},[1576],{"nctId":1577,"briefTitle":1578,"status":106,"phases":1579,"primaryCompletion":239,"completion":239,"start":1580,"enrollment":1581,"conditions":1582,"interventions":1583},"NCT00943956","Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer",[87],"2009-01",30,[26],[1570,1584,1585],"everolimus","leuprolide acetate",{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[],{"trials":1593,"activeCount":98},[],{"intervention":1584,"totalTrials":127,"cells":1595},{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1604,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[1600],{"nctId":1577,"briefTitle":1578,"status":106,"phases":1601,"primaryCompletion":239,"completion":239,"start":1580,"enrollment":1581,"conditions":1602,"interventions":1603},[87],[26],[1570,1584,1585],{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[],{"intervention":1585,"totalTrials":127,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1622,"PHASE3":1624,"PHASE4":1626,"NA":1628},{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[1618],{"nctId":1577,"briefTitle":1578,"status":106,"phases":1619,"primaryCompletion":239,"completion":239,"start":1580,"enrollment":1581,"conditions":1620,"interventions":1621},[87],[26],[1570,1584,1585],{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":98},[],{"trials":1629,"activeCount":98},[],{"intervention":1631,"totalTrials":127,"cells":1632},"NFL101",{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1645,"PHASE3":1647,"PHASE4":1649,"NA":1651},{"trials":1634,"activeCount":98},[],{"trials":1636,"activeCount":98},[1637],{"nctId":1638,"briefTitle":1639,"status":106,"phases":1640,"primaryCompletion":1641,"completion":1366,"start":874,"enrollment":145,"conditions":1642,"interventions":1644},"NCT02521701","Safety and Efficacity of NFL101 as Tobacco Therapy",[87],"2015-12",[1643],"Smoking",[1631],{"trials":1646,"activeCount":98},[],{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"intervention":1654,"totalTrials":127,"cells":1655},"TDM1",{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1671,"PHASE3":1673,"PHASE4":1675,"NA":1677},{"trials":1657,"activeCount":98},[],{"trials":1659,"activeCount":98},[1660],{"nctId":1661,"briefTitle":1662,"status":106,"phases":1663,"primaryCompletion":1664,"completion":1665,"start":1666,"enrollment":1667,"conditions":1668,"interventions":1670},"NCT02135159","Patients With Brain Metastases From HER2-positive Breast Cancer",[87],"2017-02","2017-03","2014-02",36,[1669],"HER2-positive Breast Cancer",[1654],{"trials":1672,"activeCount":98},[],{"trials":1674,"activeCount":98},[],{"trials":1676,"activeCount":98},[],{"trials":1678,"activeCount":98},[],{"intervention":148,"totalTrials":127,"cells":1680},{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1689,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[1685],{"nctId":139,"briefTitle":140,"status":106,"phases":1686,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":1687,"interventions":1688},[87],[112],[148,126,50],{"trials":1690,"activeCount":98},[],{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":98},[],{"trials":1696,"activeCount":98},[],{"intervention":205,"totalTrials":127,"cells":1698},{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1707,"PHASE3":1709,"PHASE4":1711,"NA":1713},{"trials":1700,"activeCount":98},[],{"trials":1702,"activeCount":98},[1703],{"nctId":196,"briefTitle":197,"status":106,"phases":1704,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":1705,"interventions":1706},[87],[20],[50,205,206],{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":98},[],{"trials":1714,"activeCount":98},[],{"intervention":206,"totalTrials":127,"cells":1716},{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1725,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1718,"activeCount":98},[],{"trials":1720,"activeCount":98},[1721],{"nctId":196,"briefTitle":197,"status":106,"phases":1722,"primaryCompletion":199,"completion":200,"start":201,"enrollment":202,"conditions":1723,"interventions":1724},[87],[20],[50,205,206],{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"intervention":1734,"totalTrials":127,"cells":1735},"Folfirinox + cetuximab",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":98},[],{"trials":1741,"activeCount":98},[],{"trials":1743,"activeCount":98},[],{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[1748],{"nctId":1749,"briefTitle":1750,"status":106,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1754,"conditions":1755,"interventions":1756},"NCT03914170","Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer",[],"2018-04-01","2017-04-01",70,[20],[1734],{"intervention":1758,"totalTrials":127,"cells":1759},"blood samples",{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[],{"trials":1765,"activeCount":98},[],{"trials":1767,"activeCount":98},[],{"trials":1769,"activeCount":98},[],{"trials":1771,"activeCount":98},[1772],{"nctId":1773,"briefTitle":1774,"status":106,"phases":1775,"primaryCompletion":1776,"completion":283,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1780},"NCT03252912","Study in Leptomeningeal Metastases of Breast Cancer",[91],"2020-02-03","2017-01-06",51,[15],[1758],{"intervention":1782,"totalTrials":127,"cells":1783},"Gene expression analysis",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1785,"activeCount":98},[],{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":98},[1796],{"nctId":1797,"briefTitle":1798,"status":106,"phases":1799,"primaryCompletion":1800,"completion":1801,"start":1802,"enrollment":261,"conditions":1803,"interventions":1805},"NCT00628368","Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer",[91],"2009-09","2009-09-30","2005-11",[20,1804],"Esophageal Cancer",[1782],{"intervention":1807,"totalTrials":127,"cells":1808},"Temozolomide",{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1810,"activeCount":98},[],{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[1821],{"nctId":1822,"briefTitle":1823,"status":106,"phases":1824,"primaryCompletion":174,"completion":1825,"start":504,"enrollment":1826,"conditions":1827,"interventions":1828},"NCT03257618","Quality of Life and Neurocognitive Functioning",[91],"2021-12-31",26,[31],[1807],{"intervention":1830,"totalTrials":127,"cells":1831},"epoetin beta",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1840,"NA":1842},{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"trials":1841,"activeCount":98},[],{"trials":1843,"activeCount":98},[1844],{"nctId":1845,"briefTitle":1846,"status":1011,"phases":1847,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":11,"conditions":1850,"interventions":1852},"NCT00875004","Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors",[91],"2011-12-31","2007-12-07",[1851,216],"Anemia",[1830,1853],"systemic chemotherapy",{"intervention":1853,"totalTrials":127,"cells":1855},{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"trials":1867,"activeCount":98},[1868],{"nctId":1845,"briefTitle":1846,"status":1011,"phases":1869,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":11,"conditions":1870,"interventions":1871},[91],[1851,216],[1830,1853]]